Ad
related to: health risks of sickle cell- Studies & Results
Review How LYFGENIA Was
Studied & The Results.
- Sign Up
Stay Up To Date. Sign Up For The
Latest Information About LYFGENIA.
- my bluebird support
Learn More About This Resource
For Patients On LYFGENIA.
- How Does LYFGENIA Work?
See How It Works & The
Treatment Process.
- Studies & Results
Search results
Results from the WOW.Com Content Network
Sickle cell disease (SCD), also simply called sickle cell, is a group of hemoglobin-related blood disorders that are typically inherited. [2] The most common type is known as sickle cell anemia. [2] Sickle cell anemia results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. [2]
Worldwide, 8 million people are estimated to have sickle cell disease, an inherited disorder, according to the National Institutes of Health. Most of those in the U.S. are Black.
A sickle cell health crisis can escalate into life-threatening complications, but patients still struggle to get seen quickly in emergency rooms and also to get pain medicine.
Hydroxycarbamide, also known as hydroxyurea, is an antimetabolite medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. [4] [5] In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. [4] It is taken by mouth. [4]
The sickle cell trait provides a survival advantage against malaria fatality over people with normal hemoglobin in regions where malaria is endemic. The trait is known to cause significantly fewer deaths due to malaria, especially when Plasmodium falciparum is the causative organism.
Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. Pfizer is also discontinuing all studies and access programs related to the ...
Sickle cell nephropathy is a type of kidney disease associated with sickle cell disease which causes kidney complications as a result of sickling of red blood cells in the small blood vessels. The hypertonic and relatively hypoxic environment of the renal medulla , coupled with the slower blood flow in the vasa recta , favors sickling of red ...
The FDA approved a new treatment for sickle cell disease. The therapy is first to use the ground-editing tool CRISPR. ... which carries the risk of rejection by the immune system, in addition to ...
Ad
related to: health risks of sickle cell